370 related articles for article (PubMed ID: 906404)
61. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
Deutschmann KE; Peter HH; Schultheis W; Deicher H
Tumori; 1977; 63(3):303-7. PubMed ID: 898298
[TBL] [Abstract][Full Text] [Related]
62. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
Lieberman R; Wybran J; Epstein W
Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
[TBL] [Abstract][Full Text] [Related]
63. [Prognostic significance of immunologic tests in cancer of the oral cavity].
Szpirglas H; Castet-Sardjveladzé E; Piadé R; Roth-Ghanassia V; Tsamis J
Rev Stomatol Chir Maxillofac; 1977; 78(3):207-18. PubMed ID: 329403
[TBL] [Abstract][Full Text] [Related]
64. Immunotherapy of human malignant melanoma with oil-attached BCG cell-wall skeleton.
Yamamura Y; Yoshizaki K; Azuma I; Yagura T; Watanabe T
Gan; 1975 Aug; 66(4):355-63. PubMed ID: 1102379
[TBL] [Abstract][Full Text] [Related]
65. [Clinical and immunological parallels in soft tissue tumors].
Gladikov IuV; Klimenkov AA; Kadagidze ZG; Kupin VI; Sveshinina IuA
Vopr Onkol; 1978; 24(12):3-8. PubMed ID: 735006
[TBL] [Abstract][Full Text] [Related]
66. Demonstration of lymphocyte blastogenesis--inhibiting factors in sera of melanoma patients.
Rangel DM; Golub SH; Morton DL
Surgery; 1977 Aug; 82(2):224-32. PubMed ID: 877866
[TBL] [Abstract][Full Text] [Related]
67. Immunotherapy in patients with melanoma.
Seiger HF; Shingleton WW; Metzgar RS; Buckley CE
Ann Surg; 1973 Sep; 178(3):352-9. PubMed ID: 4269702
[No Abstract] [Full Text] [Related]
68. The use of oral BCG in the treatment or metastatic malignant melanoma.
Pritchard KI; Cowan DH; Baker MA; Osoba D; Phillips RA; Clark DA
Med Pediatr Oncol; 1976; 2(2):173-81. PubMed ID: 785199
[TBL] [Abstract][Full Text] [Related]
69. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma. A sequential study over 28 days. II. Changes in non-specific (NK, K and T cell) lymphocytoxicity and delayed hypersensitivity skin reactions.
Thatcher N; Swindell R; Crowther D
Clin Exp Immunol; 1979 Feb; 35(2):171-9. PubMed ID: 312169
[TBL] [Abstract][Full Text] [Related]
70. BCG as active immunotherapy in children with acute lymphoblastic leukemia in longstanding remission: positive effects on remission duration and immunologic parameters.
Miale TD; Yocum D; Yocum C
Biomedicine; 1978 May; 28(2):96-104. PubMed ID: 276382
[TBL] [Abstract][Full Text] [Related]
71. [Unspecific, active BCG vaccination therapy in melanoma using a modified scarification procedure].
Wolf M; Menzel W; Keller G
Dermatol Monatsschr; 1978 Apr; 164(4):302-3. PubMed ID: 668966
[No Abstract] [Full Text] [Related]
72. Immunotherapy for human malignant melanoma.
Kopf AW
South Med J; 1975 Apr; 68(4):495-503. PubMed ID: 1124416
[TBL] [Abstract][Full Text] [Related]
73. [Intralesion BCG vaccine therapy in cutaneous melanoma metastasis].
Wolf M; Menzel W
Dermatol Monatsschr; 1978 Sep; 164(9):671-2. PubMed ID: 710658
[No Abstract] [Full Text] [Related]
74. Results of administering B.C.G. to patients with melanoma.
Grant RM; Mackie R; Cochran AJ; Murray EL; Hoyle D; Ross C
Lancet; 1974 Nov; 2(7889):1096-100. PubMed ID: 4139404
[No Abstract] [Full Text] [Related]
75. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.
Berd D; Mastrangelo MJ
Cancer Invest; 1988; 6(3):337-49. PubMed ID: 3167614
[TBL] [Abstract][Full Text] [Related]
76. [Clinical administration of BCG-immunotherapy in malignant melanoma (author's transl)].
Wätzig V; Knopf B
Arch Geschwulstforsch; 1979; 49(2):140-5. PubMed ID: 475550
[TBL] [Abstract][Full Text] [Related]
77. Immunological mechanisms in choroidal melanoma.
Char DH
Trans Ophthalmol Soc U K (1962); 1977 Sep; 97(3):389-93. PubMed ID: 273995
[TBL] [Abstract][Full Text] [Related]
78. [Immune profile in melanoma patients. I. PHA--stimulation of circulating lymphocytes and number of T- and B-lymphocytes (author's transl)].
Knopf B; Wätzig V; Knöll B
Arch Geschwulstforsch; 1978; 48(6):559-64. PubMed ID: 310289
[TBL] [Abstract][Full Text] [Related]
79. Effect of BCG immunotherapy on alloantigen-induced blastogenesis and cytotoxicity of lymph node lymphocytes in patients with melanoma.
Callery CD; Morton DL; Golub SH
Surg Forum; 1979; 30():152-4. PubMed ID: 161421
[No Abstract] [Full Text] [Related]
80. Immunological effects of BCG in malignant melanoma: two modes of administration compared.
Bluming AZ; Vogel CL; Ziegler JL; Mody N; Kamya G
Ann Intern Med; 1972 Mar; 76(3):405-11. PubMed ID: 5015915
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
